BEXIMCO PHARMA.GDR REGS 1 (R2WA) — Working Capital to Net Assets Ratio
BEXIMCO PHARMA.GDR REGS 1 (R2WA) has a Working Capital to Net Assets ratio of 24.4% as of December 2024. Working capital of €13.09 Billion (current assets of €24.63 Billion minus current liabilities of €11.54 Billion) is measured against net assets of €53.63 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See BEXIMCO PHARMA.GDR REGS 1 (R2WA) defensive interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
BEXIMCO PHARMA.GDR REGS 1 Working Capital to Net Assets (2021–2024)
This chart shows how BEXIMCO PHARMA.GDR REGS 1's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at 24.4%, reflecting working capital of €13.09 Billion against net assets of €53.63 Billion EUR. For the complete balance sheet picture, see BEXIMCO PHARMA.GDR REGS 1 total assets.
Annual Working Capital to Net Assets for BEXIMCO PHARMA.GDR REGS 1 (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for BEXIMCO PHARMA.GDR REGS 1 from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check R2WA financial resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 21.7% | €11.26 Billion | €51.90 Billion | €20.82 Billion | €9.56 Billion | ▲ +5.7 pp |
| 2023 | 16.0% | €7.61 Billion | €47.62 Billion | €20.88 Billion | €13.27 Billion | ▲ +3.2 pp |
| 2022 | 12.7% | €5.68 Billion | €44.64 Billion | €18.42 Billion | €12.74 Billion | ▲ +0.9 pp |
| 2021 | 11.8% | €4.42 Billion | €37.36 Billion | €13.77 Billion | €9.35 Billion | — |